Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
+ 347 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
+ 331 more sites in the U.S.
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Locations: - Clearview Cancer Institute (Crestwood) — Huntsville, Alabama
- Clearview Cancer Institute — Huntsville, Alabama
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Chandler, Arizona
+ 119 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Locations: - The University of Arizona Cancer Center - North Campus ( Site 0073) — Tucson, Arizona
- UCLA Hematology/Oncology - Santa Monica ( Site 0044) — Los Angeles, California
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) — Orange, California
+ 59 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Sponsor: Celgene
NCT ID: NCT06764485
Locations: - Central Alabama Research — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Local Institution - 0370 — Anaheim, California
+ 52 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Locations: - University of California at San Diego — La Jolla, California
- Cedars Sinai Medical Center — Los Angeles, California
- Ronald Reagan UCLA Medical Center — Los Angeles, California
+ 50 more sites in the U.S.
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Locations: - Mayo Clinic in Arizona - Phoenix ( Site 0044) — Phoenix, Arizona
- City of Hope Comprehensive Cancer Center ( Site 0049) — Duarte, California
- City of Hope Lennar Foundation Cancer Center ( Site 0059) — Irvine, California
+ 48 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial tests whether high-dose vitamin D works in treating androgen-deprivation therapy (ADT)-induced bone loss in patients with prostate cancer who are undergoing androgen-deprivation therapy. Vitamins are substances that th…
Sponsor: University of Rochester
NCT ID: NCT05838716
Locations: - Helen F Graham Cancer Center — Newark, Delaware
- Medical Oncology Hematology Consultants PA — Newark, Delaware
- Carle at The Riverfront — Danville, Illinois
+ 48 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Locations: - Arizona Clinical Trials — Chandler, Arizona
- Arkansas Urology — Little Rock, Arkansas
- MemorialCare Orange Coast Medical Center — Fountain Valley, California
+ 46 more sites in the U.S.
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06235697
Locations: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
+ 43 more sites in the U.S.
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Locations: - Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
- Palo Verde Hematology Oncology — Glendale, Arizona
+ 41 more sites in the U.S.
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Locations: - University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) — Orange, California
- Stanford Cancer Center ( Site 0036) — Palo Alto, California
- Kaiser Permanente Riverside Medical Center ( Site 0099) — Riverside, California
+ 41 more sites in the U.S.